XANTHINE OXIDASE INHIBITOR FORMULATIONS

(19)

(11)

EP 3 001 814 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.07.2021 Bulletin 2021/27

(45)	Mention of the grant of the patent:
	19.05.2021 Bulletin 2021/20

(21)	Application number: 14764884.4

(22)	Date of filing: 17.03.2014

(51)

International Patent Classification (IPC):

A61K 47/18^(2017.01)
A61K 31/519^(2006.01)
A61K 9/14^(2006.01)
A61P 3/00^(2006.01)
A61K 31/197^(2006.01)
A61K 31/4188^(2006.01)
A61K 31/455^(2006.01)
A61K 31/525^(2006.01)
A61K 31/714^(2006.01)

A61K 47/22^(2006.01)
A61K 9/08^(2006.01)
A61P 19/06^(2006.01)
A61K 9/00^(2006.01)
A61K 31/198^(2006.01)
A61K 31/4415^(2006.01)
A61K 31/51^(2006.01)
A61K 31/593^(2006.01)
A61K 31/375^(2006.01)

(86)	International application number:
	PCT/IB2014/001042

(87)	International publication number:
	WO 2014/140868 (18.09.2014 Gazette 2014/38)

(54)	XANTHINE OXIDASE INHIBITOR FORMULATIONS FORMULIERUNGEN FÜR XANTHINOXIDASEHEMMER FORMULATIONS D'INHIBITEUR DE XANTHINE OXYDASE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

15.03.2013 US 201361790414 P

(43)	Date of publication of application:
	06.04.2016 Bulletin 2016/14

(60)	Divisional application:
	21174259.8

(73)	Proprietor: XORTX Therapeutics Inc.
	Calgary, Alberta T2P 4K9 (CA)

(72)	Inventors:
	Allen, Davidoff Calgary, AB T3H 5Z7 (CA) Boivin, Taryn Surrey, BC V4A 9W5 (CA)

(74)	Representative: Di Giovine, Paolo et al
	Società Italiana Brevetti S.p.A. Piazza di Pietra, 38-39 00186 Roma 00186 Roma (IT)

(56)

References cited: :

WO-A1-2006/083687
WO-A1-2011/097269
CA-A1- 2 519 126
US-A- 5 661 154
US-B1- 6 569 862

WO-A1-2007/044910
WO-A1-2012/098501
US-A- 5 484 605
US-B1- 6 544 726

AMMAR H O ET AL: "SOLUBILIZATION OF ALLOPURINOL WITH METHYL XANTHINES", DIE PHARMAZIE: AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, DE, vol. 49, no. 11, 1 November 1994 (1994-11-01), pages 839-842, XP000476672, ISSN: 0031-7144
Atsushi Hirano ET AL: "Arginine-Assisted Solubilization System for Drug Substances: Solubility Experiment and Simulation", The Journal of Physical Chemistry B, vol. 114, no. 42, 28 October 2010 (2010-10-28), pages 13455-13462, XP055046746, ISSN: 1520-6106, DOI: 10.1021/jp101909a

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).